Last $6.97 USD
Change Today -0.005 / -0.07%
Volume 1.3M
FOLD On Other Exchanges
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (FOLD) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/14 - $7.63
52 Week Low
04/16/14 - $1.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

amicus therapeutics inc (FOLD) Related Bloomberg News

View More Bloomberg News

amicus therapeutics inc (FOLD) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (FOLD) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company’s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

92 Employees
Last Reported Date: 03/3/14
Founded in 2002

amicus therapeutics inc (FOLD) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $824.1K
Chief Financial Officer and Secretary
Total Annual Compensation: $445.1K
Chief Operating Officer
Total Annual Compensation: $475.0K
Principal Accounting Officer, Vice President ...
Total Annual Compensation: $247.4K
Compensation as of Fiscal Year 2013.

amicus therapeutics inc (FOLD) Key Developments

Amicus Therapeutics Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Net Cash Spend Guidance for the Full Year 2014; Provides Program Updates

Amicus Therapeutics announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the third quarter, the company reported total revenue of $293,000 against $39,000 a year ago. Loss from operations was $16,816,000 against $15,135,000 a year ago. Net loss was $17,149,000 or $0.22 per basic and diluted share against $14,589,000 or $0.29 per basic and diluted share a year ago. For the nine months, the company reported total revenue of $1,224,000 against $39,000 a year ago. Loss from operations was $46,703,000 against $48,391,000 a year ago. Net loss was $47,706,000 or $0.68 per basic and diluted share against $47,396,000 or $0.96 per basic and diluted share a year ago. The company provided net cash spend guidance for the full year 2014. For the year, the company continues to expect full-year 2014 net cash spend of between $54 million and $59 million. The company announced that it is developing its wholly owned pharmacological chaperone migalastat HCl (migalastat) monotherapy for the treatment of people with Fabry disease. As a monotherapy, migalastat is designed to bind and stabilize alpha-Gal A enzyme in patients with amenable mutations. Migalastat monotherapy is being investigated in two phase 3 registration studies (Study 011 and Study 012) and an open-label extension study (Study 041) in Fabry patients with amenable mutations. Positive phase 3 results from study 011 reported at american society of human genetics (ASHG) annual meeting: In October 2014, positive results from Study 011 and Study 041 were presented in a poster at ASHG by Daniel G. Bichet, M.D., M.Sc., Professor, Department of Physiology, University of Montreal. Data presented showed that patients receiving migalastat for an average of 32 months showed continued stability of kidney function and compared favorably to published natural history in Fabry disease. Decline in kidney function is a key cause of morbidity and mortality in patients with Fabry disease. Data from Study 012 will be presented at a scientific congress for the first time at the American Society of Nephrology (ASN) Kidney Week 2014 in Philadelphia on November 15, 2014. The data will be in a poster entitled Migalastat and Enzyme Replacement Therapy Have Comparable Effects on Renal Function in Fabry Disease: Phase 3 study results. This presentation will also include important new data on cardiac and other key secondary endpoints from Study 012. Based on the positive results from Study 012, Amicus expects to submit a marketing application for migalastat monotherapy in Europe, and is scheduled to meet with the European Medicines Agency in the fourth quarter of this year. Amicus also plans to meet with the U.S. Food and Drug Administration in the first quarter of 2015 to discuss the data from both Phase 3 Fabry monotherapy studies to determine the fast U.S. registration pathway for migalastat.

Amicus Therapeutics, Inc., Q3 2014 Earnings Call, Nov 06, 2014

Amicus Therapeutics, Inc., Q3 2014 Earnings Call, Nov 06, 2014

Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011

Amicus Therapeutics announced additional positive data from a Phase 3 study (Study 011) of the oral small molecule chaperone migalastat HCl ("migalastat") in Fabry disease patients with amenable mutations. Assessment of kidney function by various measures of glomerular filtration rate (GFR) for patients receiving migalastat in Study 011 for at least 18 months and continuing migalastat treatment in Study 041 showed continued stability of kidney function for an average of 32 months. Decline in kidney function is a key cause of morbidity and mortality in patients with Fabry disease. Measured (iohexol) GFR (mGFR) showed stability over 18-24 months in Study 011 but was not collected in Study 041; mGFR was previously reported with topline Study 011 results. Stratifying patients for gender and baseline proteinuria demonstrated that patients treated with migalastat experienced less decline in kidney function than untreated patients from a previously published natural history study. Data from a subgroup analysis comparing the change in GL-3 substrate levels between amenable patients and non-amenable patients based on the GLP HEK cell assay provided additional validation of the sensitivity of the GLP HEK assay for identifying patients who will respond to migalastat monotherapy. Overall, patients with amenable mutations had declining levels of GL-3 when treated for six months with migalastat. In contrast, patients with non-amenable mutations had no change or increasing levels of GL-3 after six months of migalastat treatment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $6.97 USD -0.005

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies

Industry Analysis


Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 355.0x
Price/Book 12.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 354.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at